Background: Previous investigations have suggested a significant association between inflammatory bowel disease (IBD) and atopic dermatitis (AD). Yet, outcomes published remain inconsistent. Objective: To explore the association between IBD and AD by a systematic review and meta-analysis. Methods: A comprehensive search of studies published from March 1, 1968, to July 26, 2019, was performed in electronic databases as follows: PubMed, Embase, Cochrane Library, and Web of Science. Methodological quality was assessed based on the Newcastle-Ottawa Scale. Data analysis was conducted using R version 3.6.1 (meta package version 4.9-7). Results: A total of 14 studies were eligible for exploring the association between IBD and AD. Statistically significant differences were found on the risk of AD comorbidity among patients with IBD (risk ratio [RR] 1.83, 95% CI 1.39–2.40), Crohn’s disease (CD; RR 2.06, 95% CI 1.61–2.64), and ulcerative colitis (UC; RR 1.66, 95% CI 1.23–2.24). Compared with non-AD subjects, patients with AD were 48% (p = 0.019), 44% (p = 0.002), and 38% (p = 0.000) more likely to exhibit IBD, CD as well as UC, respectively. Discussion: Our evidence supported a significant bidirectional association between IBD and AD. Future prospective studies are warranted to explore underlying mechanisms linking them.

Keywords:
Atopic dermatitis, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Meta-analysis
This content is only available via PDF.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.